S&P 500   3,357.66 (+0.19%)
DOW   27,720.74 (+1.05%)
QQQ   269.90 (-0.58%)
AAPL   449.66 (+1.17%)
MSFT   207.80 (-2.20%)
FB   262.25 (-2.31%)
GOOGL   1,491.40 (-0.47%)
AMZN   3,143.48 (-0.76%)
NVDA   448.93 (+0.21%)
CGC   18.04 (+8.48%)
BABA   248.22 (-1.54%)
TSLA   1,424.00 (-1.98%)
MU   49.37 (+1.27%)
GE   6.64 (+3.75%)
AMD   82.21 (-3.11%)
T   30.14 (+0.40%)
F   7.10 (+3.50%)
ACB   10.25 (-0.19%)
GILD   68.29 (-1.53%)
NFLX   485.73 (-1.82%)
DIS   129.18 (-0.58%)
BAC   26.55 (+1.69%)
BA   176.38 (+3.74%)
S&P 500   3,357.66 (+0.19%)
DOW   27,720.74 (+1.05%)
QQQ   269.90 (-0.58%)
AAPL   449.66 (+1.17%)
MSFT   207.80 (-2.20%)
FB   262.25 (-2.31%)
GOOGL   1,491.40 (-0.47%)
AMZN   3,143.48 (-0.76%)
NVDA   448.93 (+0.21%)
CGC   18.04 (+8.48%)
BABA   248.22 (-1.54%)
TSLA   1,424.00 (-1.98%)
MU   49.37 (+1.27%)
GE   6.64 (+3.75%)
AMD   82.21 (-3.11%)
T   30.14 (+0.40%)
F   7.10 (+3.50%)
ACB   10.25 (-0.19%)
GILD   68.29 (-1.53%)
NFLX   485.73 (-1.82%)
DIS   129.18 (-0.58%)
BAC   26.55 (+1.69%)
BA   176.38 (+3.74%)
S&P 500   3,357.66 (+0.19%)
DOW   27,720.74 (+1.05%)
QQQ   269.90 (-0.58%)
AAPL   449.66 (+1.17%)
MSFT   207.80 (-2.20%)
FB   262.25 (-2.31%)
GOOGL   1,491.40 (-0.47%)
AMZN   3,143.48 (-0.76%)
NVDA   448.93 (+0.21%)
CGC   18.04 (+8.48%)
BABA   248.22 (-1.54%)
TSLA   1,424.00 (-1.98%)
MU   49.37 (+1.27%)
GE   6.64 (+3.75%)
AMD   82.21 (-3.11%)
T   30.14 (+0.40%)
F   7.10 (+3.50%)
ACB   10.25 (-0.19%)
GILD   68.29 (-1.53%)
NFLX   485.73 (-1.82%)
DIS   129.18 (-0.58%)
BAC   26.55 (+1.69%)
BA   176.38 (+3.74%)
S&P 500   3,357.66 (+0.19%)
DOW   27,720.74 (+1.05%)
QQQ   269.90 (-0.58%)
AAPL   449.66 (+1.17%)
MSFT   207.80 (-2.20%)
FB   262.25 (-2.31%)
GOOGL   1,491.40 (-0.47%)
AMZN   3,143.48 (-0.76%)
NVDA   448.93 (+0.21%)
CGC   18.04 (+8.48%)
BABA   248.22 (-1.54%)
TSLA   1,424.00 (-1.98%)
MU   49.37 (+1.27%)
GE   6.64 (+3.75%)
AMD   82.21 (-3.11%)
T   30.14 (+0.40%)
F   7.10 (+3.50%)
ACB   10.25 (-0.19%)
GILD   68.29 (-1.53%)
NFLX   485.73 (-1.82%)
DIS   129.18 (-0.58%)
BAC   26.55 (+1.69%)
BA   176.38 (+3.74%)
Log in

NASDAQ:GALTGalectin Therapeutics Stock Price, Forecast & News

Add
Compare
Today's Range N/A
50-Day Range
$2.56
MA: $2.80
$3.11
52-Week Range N/A
Volume89,273 shs
Average Volume126,580 shs
Market Capitalization$155.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43
Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.
Read More
Galectin Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GALT
CUSIPN/A
Phone678-620-3186

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.76 per share

Profitability

Net Income$-13,290,000.00

Miscellaneous

Employees6
Market Cap$155.69 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive GALT News and Ratings via Email

Sign-up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Galectin Therapeutics (NASDAQ:GALT) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Galectin Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Galectin Therapeutics
.

When is Galectin Therapeutics' next earnings date?

Galectin Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020.
View our earnings forecast for Galectin Therapeutics
.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Monday, May, 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.02.
View Galectin Therapeutics' earnings history
.

What price target have analysts set for GALT?

2 brokers have issued 12-month target prices for Galectin Therapeutics' shares. Their forecasts range from $4.00 to $9.00. On average, they anticipate Galectin Therapeutics' share price to reach $6.50 in the next twelve months.
View analysts' price targets for Galectin Therapeutics
.

Has Galectin Therapeutics been receiving favorable news coverage?

News coverage about GALT stock has been trending very positive recently, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Galectin Therapeutics earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Galectin Therapeutics
.

Who are some of Galectin Therapeutics' key competitors?

What other stocks do shareholders of Galectin Therapeutics own?

Who are Galectin Therapeutics' key executives?

Galectin Therapeutics' management team includes the following people:
  • Dr. Harold H. Shlevin, Pres & CEO (Age 69)
  • Mr. Jack W. Callicutt, CFO & Sec. (Age 52)
  • Robert Tritt, Gen. Counsel
  • Dr. Eliezer Zomer, Exec. VP of Manufacturing & Product Devel. (Age 72)
  • Mr. J. Rex Horton, Exec. Director of Regulatory Affairs & Quality Assurance (Age 49)

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.02%). Company insiders that own Galectin Therapeutics stock include Fund LP 10X, Gilbert F Amelio, Gilbert S Omenn, Jack W Callicutt, Kary Eldred, Kevin D Freeman, Marc Rubin and Richard E Uihlein.
View institutional ownership trends for Galectin Therapeutics
.

Which institutional investors are selling Galectin Therapeutics stock?

GALT stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Galectin Therapeutics
.

How do I buy shares of Galectin Therapeutics?

Shares of GALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Galectin Therapeutics?

Galectin Therapeutics has a market capitalization of $0.00. The company earns $-13,290,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Galectin Therapeutics employs 6 workers across the globe.

What is Galectin Therapeutics' official website?

The official website for Galectin Therapeutics is www.galectintherapeutics.com.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The company can be reached via phone at 678-620-3186 or via email at [email protected]

This page was last updated on 8/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.